Pioneering the development of CRISPR/Cas9 genome editing
Co-founded by Jennifer Doudna, 2020 Nobel Prize winner in Chemistry, Intellia Therapeutics is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic. The company employs a modular genome editing platform to create diverse in vivo and ex vivo pipelines that span a range of therapeutic indications.
|Difficulty finding data across multiple systems|
Previous registration took place across SharePoint spreadsheets, emails, and paper, leading to unreliable data and outsize time spent piecing together lineages.
|Tracking and updating plasmid inventory|
Plasmid repositories couldn’t be tracked and kept up to date.
|Inefficient request fulfillment|
Lack of a formal request system led to lost requests and insufficient detail in requests. Without a reliable plasmid inventory, certain requests were difficult to complete.
Standardized lists of plasmids and other entities make data reliable and easily shared.
|Streamlined request triaging|
With Benchling Requests, teams generate greater throughput and higher quality products because they can easily access the information they need.
|Generating R&D insights|
Benchling Workflows empowers Intellia to identify the upstream entities that lead to successful batches.